Dermatologic Overview of Lupus Erythematosus and Its Subsets

Moschella, Samuel L.

doi:10.1111/j.1346-8138.1989.tb01581.x

Cited by 12 publications

(2 citation statements)

References 80 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The female-to-male ratio was 3.2:1 in our SCLE subjects. Earlier studies have shown that there is likewise a female predominance in SCLE, with women affected 3-6 times more frequently than men 16, 31, 41. The female-to-male ratio in our CCLE subjects of 4.1:1 is somewhat higher than reported ratios of 3:1 35, 42, 43.…”

Section: Discussioncontrasting

confidence: 58%

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Moghadam-Kia

Chilek²,

Gaines³

et al. 2009

Arch Dermatol

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 58%

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Moghadam-Kia

Chilek²,

Gaines³

et al. 2009

Arch Dermatol

View full text Add to dashboard Cite

“…Frauen sind deutlich häufiger betroffen mit einem Überwiegen von 3 : 1 beim CDLE und 3 ± 6 : 1 beim SCLE. Neben dem klassischen, LEspezifischen Hautbefund zeigen viele Patienten LE-unspezifische Hautbefunde wie akrolokalisierte Vaskulitis (4 ± 30 %), Livedo racemosa (22 ± 35 %) und diffuser Haarausfall (38 ± 78 %) [3,36,54].…”

unclassified

Alte Substanzen, neue Erkenntnisse: Immunmodulatoren und Immunsuppressiva beim kutanen Lupus erythematodes

Tebbe¹

2003

Akt Dermatol

View full text Add to dashboard Cite

EinleitungDer systemische Lupus erythematodes (SLE) ist eine der häufigs-ten Autoimmunkrankheiten. Prävalenzraten variieren weltweit zwischen 14 und 50/100 000 in der Bevölkerung [24]. Zum kutanen Lupus erythematodes gibt es demgegenüber keine gut dokumentierten, epidemiologischen Studien. Wahrscheinlich ist der kutane LE jedoch 2 ± 3-mal häufiger als der SLE. Die Prognose des SLE wird durch die Schwere und die Ausdehnung der inneren AbstractFor therapy of cutaneous lupus erythematosus the precise classification of the clinical subset is necessary. The most frequently found LE subsets are chronic discoid LE (CDLE) and subacute cutaneous LE (SCLE). Extension of the cutaneous lesions and presence of visceral involvement are criteria for therapy choice. Basic therapeutics for cutaneous LE are antimalarials (chloroquine, hydroxychloroquine) alone or in combination with systemic corticosteroids. For visceral involvement others than arthralgia/arthritis azathioprin is the first line therapy. In 80 ± 90 % of the patients disease can be controlled by these standard therapies. In the remaining cases oral retinoids, thalidomide, methotrexate or diaminodiphenylsulfon can be tried. Recently, a few case reports have been published on a good therapeutic effect of local tacrolimus and systemic mycophenolate mofetil in cutaneous LE. Originalarbeit 403Dieses Dokument wurde zum persönlichen Gebrauch heruntergeladen. Vervielfältigung nur mit Zustimmung des Verlages.

show abstract

Association of Cutaneous Lupus Erythematosus with Other Dermatological Diseases

Pramatarov¹,

Tsankov²

Cutaneous Lupus Erythematosus

View full text Add to dashboard Cite

Dermatologic Overview of Lupus Erythematosus and Its Subsets

Cited by 12 publications

References 80 publications

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Alte Substanzen, neue Erkenntnisse: Immunmodulatoren und Immunsuppressiva beim kutanen Lupus erythematodes

Association of Cutaneous Lupus Erythematosus with Other Dermatological Diseases

Contact Info

Product

Resources

About